Fatal outcome related to carmustine implants in glioblastoma multiforme.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17334672.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival. However, some precautions should be taken regarding Gliadel implantation. We report three cases in whom patients with glioblastoma multiforme were implanted with fibrin glue-secured Gliadel after the lateral ventricles had been opened, and who later developed severe hydrocephalus leading to death. Although Gliadel may be an important adjunct to treatment, opening of the ventricles during surgery as part of its application should be considered a contra-indication.
Medical subject headings
- Antineoplastic Agents, Alkylating
- Brain Neoplasms
- Carmustine
- Glioblastoma
- Hydrocephalus
- Temporal Lobe